Generic name: revefenacin systemic; Drug class: anticholinergic bronchodilators; For consumers: dosage, interactions, side effects; For
Revefenacin has been reported to produce a sustained, long-acting bronchodilation with lower anti-muscarinic-related side effects. In clinical trials, revefenacin demonstrated to be of a long duration of action and low systemic exposure in patients with COPD.
Revefenacin (Yupelri). Yupelri (revefenacin) is a once-daily nebulized LAMA approved for the maintenance treatment of patients with COPD. It provides an option
Revefenacin has been reported to produce a sustained, long-acting bronchodilation with lower anti-muscarinic-related side effects. In clinical trials
antimuscarinic side effects as Cmax and Area. Under the Curve(AUC) of revefenacin and its active metabolite increased up to 2.5-fold in patients with severe
Concurrent use of Revefenacin with other anticholinergic drugs can amplify the risk of anticholinergic side effects such as dry mouth, constipation, urinary
anticholinergic side effects. In the pooled data for Studies 0126 gestation day 6 to lactation day 20, revefenacin had no adverse.
Revefenacin exerts its therapeutic effects through: Revefenacin has been side effects. In clinical trials, revefenacin demonstrated to be of a long
(revefenacin) inhalation solution, the Tell your healthcare provider if you get any side effects that bother you or that do not go away.
Comments
one of my own pet peeves, sorry